Table 1. Patient Characteristics.
| Erlotinib + celecoxib (n= 54) |
Erlotinib + placebo (n= 53) |
||
|---|---|---|---|
| Age (range) | Median/yr | 63.5 (41-80) | 65 (30-80) |
| Male/Female | 26/28 | 24/29 | |
| Race (%) | White | 37 (69) | 35 (66) |
| Black of African American | 3 (6) | 2 (4) | |
| Asian | 12 (22) | 14 (26) | |
| American Indian | 0 | 1 (2) | |
| Not available | 2 (4) | 1 (2) | |
| ECOG PS (%) | 0 | 26 (48) | 26 (49) |
| 1 | 28 (52) | 27 (51) | |
| Histology (%) | Adenocarcinoma* | 32 (55) | 32 (60) |
| Squamous cell | 6 (11) | 5 (9) | |
| NSCLC NOS | 15 (28) | 16 (30) | |
| Not available | 1 (2) | 0 | |
| Smoking status (%) | < 100 cigarettes | 20 (37) | 20(38) |
| Former | 30 (56) | 31 (59) | |
| Current | 4 (7) | 2 (3) | |
| Stage (%) | IIIB | 6 (11) | 4 (8) |
| IV | 48 (89) | 49 (92) | |
| EGFR mutation (%) | Positive | 12 (22) | 14 (26) |
| Negative | 31 (57) | 27 (51) | |
| Not available | 11 (21) | 12 (23) | |
| Number of prior systemic therapies (%) | 0 | 6 (11) | 7 (13) |
| 1 | 27 (50) | 27 (51) | |
| 2 | 15 (28) | 11 (21) | |
| >2 | 6 (11) | 8 (15) | |
*
Includes 1 adenosquamous histology.
ECOG PS, Eastern Cooperative Oncology Group performance status.